Institute of Biomedical Sciences Abel Salazar, Porto University, Portugal.
Differentiation. 2012 Dec;84(5):355-65. doi: 10.1016/j.diff.2012.10.001. Epub 2012 Nov 7.
Cellular systems implanted into an injured nerve may produce growth factors or extracellular matrix molecules, modulate the inflammatory process and eventually improve nerve regeneration. In the present study, we evaluated the therapeutic value of human umbilical cord matrix MSCs (HMSCs) on rat sciatic nerve after axonotmesis injury associated to Vivosorb® membrane. During HMSCs expansion and differentiation in neuroglial-like cells, the culture medium was collected at 48, 72 and 96 h for nuclear magnetic resonance (NMR) analysis in order to evaluate the metabolic profile. To correlate the HMSCs ability to differentiate and survival capacity in the presence of the Vivosorb® membrane, the [Ca(2+)]i of undifferentiated HMSCs or neuroglial-differentiated HMSCs was determined by the epifluorescence technique using the Fura-2AM probe. The Vivosorb® membrane proved to be adequate and used as scaffold associated with undifferentiated HMSCs or neuroglial-differentiated HMSCs. In vivo testing was carried out in adult rats where a sciatic nerve axonotmesis injury was treated with undifferentiated HMSCs or neuroglial differentiated HMSCs with or without the Vivosorb® membrane. Motor and sensory functional recovery was evaluated throughout a healing period of 12 weeks using sciatic functional index (SFI), extensor postural thrust (EPT), and withdrawal reflex latency (WRL). Stereological analysis was carried out on regenerated nerve fibers. In vitro investigation showed the formation of typical neuroglial cells after differentiation, which were positively stained for the typical specific neuroglial markers such as the GFAP, the GAP-43 and NeuN. NMR showed clear evidence that HMSCs expansion is glycolysis-dependent but their differentiation requires the switch of the metabolic profile to oxidative metabolism. In vivo studies showed enhanced recovery of motor and sensory function in animals treated with transplanted undifferentiated and differentiated HMSCs that was accompanied by an increase in myelin sheath. Taken together, HMSC from the umbilical cord Wharton jelly might be useful for improving the clinical outcome after peripheral nerve lesion.
植入受损神经的细胞系统可能会产生生长因子或细胞外基质分子,调节炎症过程,最终改善神经再生。在本研究中,我们评估了人脐带基质 MSC(HMSC)在轴索切断伤后联合 Vivosorb®膜对大鼠坐骨神经的治疗价值。在 HMSC 向神经胶质样细胞分化的过程中,收集培养 48、72 和 96 小时的培养基,进行核磁共振(NMR)分析,以评估代谢谱。为了评估 Vivosorb®膜对 HMSC 分化能力和存活率的影响,使用 Fura-2AM 探针通过荧光显微镜技术测定未分化 HMSC 或神经胶质分化 HMSC 的[Ca(2+)]i。Vivosorb®膜被证明是合适的,并与未分化的 HMSC 或神经胶质分化的 HMSC 一起用作支架。在成年大鼠中进行体内测试,对坐骨神经轴索切断伤进行未分化的 HMSC 或神经胶质分化的 HMSC 治疗,联合或不联合 Vivosorb®膜。使用坐骨神经功能指数(SFI)、伸肌姿势推力(EPT)和撤回反射潜伏期(WRL)在 12 周的愈合期内评估运动和感觉功能的恢复情况。在再生神经纤维上进行立体学分析。体外研究表明分化后形成典型的神经胶质细胞,这些细胞对典型的神经胶质特异性标志物如 GFAP、GAP-43 和 NeuN 呈阳性染色。NMR 清楚地表明,HMSC 的扩增依赖于糖酵解,但它们的分化需要代谢谱向氧化代谢的转变。体内研究表明,移植未分化和分化的 HMSC 可增强动物的运动和感觉功能恢复,同时增加髓鞘。综上所述,脐带华通氏胶中的 MSC 可能有助于改善周围神经损伤后的临床转归。